Home  |  Contact

Cellosaurus U266/BR (CVCL_VJ36)

[Text version]

Cell line name U266/BR
Accession CVCL_VJ36
Resource Identification Initiative To cite this cell line use: U266/BR (RRID:CVCL_VJ36)
Comments Characteristics: Produces IgE lambda.
Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for BRAF p.Lys601Asn (c.1803A>T) (from parent cell line).
Heterozygous for MSH6 p.Gly141Asp (c.422G>A) (from parent cell line).
Homozygous for TP53 p.Ala161Thr (c.481G>A) (ClinVar=VCV000161518) (from parent cell line).
Homozygous for TRAF3 p.Lys550Leufs*3 (c.1648_1649insT) (from parent cell line).
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0566 (U266B1)
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line

PubMed=25382610; DOI=10.1038/bcj.2014.74
Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.-K.K., Ailawadhi S., Knight J., Heckman M.G., Pinkerton A., Chanan-Khan A.A.
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia.
Blood Cancer J. 4:E260-E260(2014)

Entry history
Entry creation07-Sep-2018
Last entry update02-Jul-2020
Version number3